MedTrace Logo

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

NCT00820950 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2022-02-08

Study results available
· View outcomes & findings →

Summary

The study is comprised of two parts. The first portion of this study will be a double-blind, Sponsor-unblinded, vehicle-controlled study with application of ruxolitinib or vehicle to paired lesions at least 15 cm apart in patients with active but stable plaque psoriasis. Part 2 of the study is a double-blind, sponsor unblinded, comparison of ruxolitinib with two FDA approved products in patients with active but stable plaque psoriasis.

Conditions

Interventions

DRUG

Ruxolitinib phosphate cream

Ruxolitinib phosphate cream 0.5%

DRUG

Dovonex® calcipotriene 0.005%

Cream applied once or twice daily for up to 56 days.

DRUG

Diprolene® AF betamethasone dipropionate 0.05% cream.

Cream applied once or twice daily for up to 56 days

DRUG

Placebo cream

Cream applied once or twice daily for 56 days

DRUG

Ruxolitinib phosphate cream

Ruxolitinib phosphate cream 1.0%

DRUG

Ruxolitinib phosphate cream

Ruxolitinib phosphate cream 1.5%

Sponsors & Collaborators

Principal Investigators

  • William Williams, MD · Incyte Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2009-01-31
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00820950 on ClinicalTrials.gov